Does the Use of Highly Purified Human Menopausal Gonadotrophin (HP-HMG) avoid Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovary (PCO) Patients in Assisted Reproduction (IVF/ICSI)?
Author(s): Elmahaishi Asma and Mohammed Said ElmahaishiElmahaishi Asma and Mohammed Said Elmahaishi
Objective: To evaluate the role of highly purified HMG (Diclair from BBT) in preventing OHSS in polycystic ovary (PCO) patients. Design: Prospective study from 1st Aug, 2012 until end of July, 2013 for one year. Setting: Lamis IVF center, Misurata LIBYA. Patient(s): During one year of study, 800 patients were treated for ICSI procedure. The 20% from these cases were diagnosed as polycystic ovary. Main outcome measure(s): Diagnosed of polycystic ovary, Age distribution, Fixed dose of 450 Iu of HP HMG from BBT/day, IVF outcome and any OHSS or admission. Result(s): age distribution counted from 20 yrs to 44 yrs old. Their eggs and embryos Quality were very good. Pregnancy rate and presence of OHSS. Conclusion: using highly purified HMG.. View More»